Director Kathy L. Hibbs of SOPHiA GENETICS SA filed a Form 4 on September 10, 2026, reporting the sale of 6,250 ordinary shares on September 8, 2026, pursuant to a Rule 10b5-1(c) trading plan.

Key Highlights

  • Shares sold: Kathy L. Hibbs disposed of 6,250 ordinary shares of SOPHiA GENETICS SA on September 8, 2026.
  • Weighted average price: The reported sale price was $8.1308 per share, a weighted average across multiple transactions.
  • Price range: Individual transactions occurred at prices ranging from $7.90 to $8.35, inclusive.
  • Post-transaction ownership: Following the sale, Hibbs directly beneficially owned 96,992 ordinary shares.
  • 10b5-1 plan: The transaction was made pursuant to a duly adopted trading plan under Rule 10b5-1(c).
  • Role: Hibbs is identified as a Director of SOPHiA GENETICS SA (NASDAQ:SOPH).

Director Kathy L. Hibbs Reports Planned Share Sale at SOPHiA GENETICS

According to the Form 4 filed with the U.S. Securities and Exchange Commission on September 10, 2026, Kathy L. Hibbs, a Director of SOPHiA GENETICS SA (NASDAQ:SOPH), disposed of 6,250 ordinary shares on September 8, 2026. The filing indicates the transaction was executed under a Rule 10b5-1(c) trading plan, as reflected by the "S" transaction code and the corresponding footnote disclosure.

The filing reports a weighted average sale price of $8.1308 per share. As noted in the filing's footnotes, the shares were sold across multiple transactions at prices ranging from $7.90 to $8.35, inclusive. The filing states that Hibbs "undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote." The form was signed by Elimara Brunetto as Attorney-in-Fact for Kathy L. Hibbs.

Following the reported transaction, Hibbs directly beneficially owned 96,992 ordinary shares of SOPHiA GENETICS SA. No derivative securities transactions were reported in Table II of the filing. The filing does not indicate any indirect beneficial ownership positions.

What Was Disclosed

Director Kathy L. Hibbs reported selling 6,250 ordinary shares of SOPHiA GENETICS SA on September 8, 2026, at a weighted average price of $8.1308, under a pre-established Rule 10b5-1(c) plan, leaving her with 96,992 directly held shares.